AcuCort says Zeqmelit oral film wins 69% patient preference in real-world study

• AcuCort flagged peer-reviewed publication of results from its ZEQ001 real-world clinical study on Zeqmelit patient preferences.
• Results have already been presented via the journal article, not scheduled for a future conference readout.
• Patients favored the orally disintegrating film over conventional tablets, citing easier use, greater convenience, and stronger confidence in access.
• The findings suggest stronger uptake potential among patients who need to stay prepared for sudden allergic-reaction treatment.
• Six-month follow-up indicated a clear preference skew toward Zeqmelit, supporting its commercial positioning versus existing tablet alternatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief via Cision (Ref. ID: 202608260220BITN____UKPR__EN_20260825-BIT-1740-0) on August 26, 2026, and is solely responsible for the information contained therein.